RobinKateKelleyMD
Oncology • San Francisco, CAProfessor of Clinical Medicine, UCSF School of Medicine
Dr. Kelley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1825 4th St
San Francisco, CA 94143Phone+1 415-353-9888Fax+1 415-353-9931- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2002 - 2005
David Geffen School of Medicine at UCLAClass of 2002
Certifications & Licensure
CA State Medical License 2003 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
- A Study of LY2157299 in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Mar 30
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
- Join now to see all
Publications & Presentations
PubMed
- Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.Manal M Hassan, Donghui Li, Younghun Han, Jinyoung Byun, Rikita I Hatia, Erping Long, Jiyeon Choi, Robin Kate Kelley, Sean P Cleary, Anna S Lok, Paige Bracci, Jennifer...> ;Hepatology. 2024 Feb 20
- 1 citationsCabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.Yau, T., Kaseb, A., Cheng, A., Qin, S., Zhu, A., Chan, S., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J., Ryoo, B., M...> ;The Lancet. Gastroenterology & Hepatology. 2024 Apr 1
- Author Correction: Hepatocellular carcinoma.Llovet, J., Villanueva, A., Pikarsky, E., Lencioni, R., Koike, K., Zucman-Rossi, J., Kelley, R., Singal, A., Roayaie, S., Finn, R.> ;Nature Reviews. Disease Primers. 2024 Feb 12
- Join now to see all
Lectures
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC...2019 ASCO Annual Meeting - 6/1/2019
- Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Atezolizumab plus Bevacizumab — A Landmark in Liver CancerMay 2020
Press Mentions
American Association for Cancer Research, April 14-19May 8th, 2023- Fears Rise That UC Strike Could Have Long-Lasting Consequences on Vaunted Research, TeachingNovember 28th, 2022
- Priming Tremelimumab Dose Regimen Shows Promising Benefit-Risk Profile in HCCOctober 19th, 2021
- Join now to see all
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
San Francisco VA Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
